Q3 EPS Estimates for Journey Medical Cut by Roth Capital

Journey Medical Co. (NASDAQ:DERM) – Analysts at Roth Capital decreased their Q3 2025 earnings estimates for Journey Medical in a research note issued on Monday, November 4th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings per share of $0.20 for the quarter, down from their prior forecast of $0.24. The consensus estimate for Journey Medical’s current full-year earnings is ($1.04) per share. Roth Capital also issued estimates for Journey Medical’s Q4 2025 earnings at $0.32 EPS and FY2025 earnings at $0.43 EPS.

Journey Medical (NASDAQ:DERM) last issued its earnings results on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The firm had revenue of $14.86 million during the quarter, compared to the consensus estimate of $13.81 million. Journey Medical had a net margin of 1.09% and a return on equity of 5.44%. During the same period in the previous year, the company posted ($0.46) earnings per share.

Several other equities research analysts also recently issued reports on the company. Rodman & Renshaw initiated coverage on Journey Medical in a report on Thursday, August 22nd. They set a “buy” rating and a $9.00 price target for the company. Lake Street Capital assumed coverage on shares of Journey Medical in a research note on Friday, September 6th. They set a “buy” rating and a $9.00 target price for the company. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Journey Medical has an average rating of “Buy” and an average price target of $9.38.

Journey Medical Stock Performance

DERM opened at $5.71 on Wednesday. The company has a quick ratio of 1.08, a current ratio of 1.36 and a debt-to-equity ratio of 1.75. Journey Medical has a 12-month low of $2.85 and a 12-month high of $8.11. The business has a 50 day moving average of $5.55 and a 200-day moving average of $4.97. The stock has a market cap of $118.37 million, a price-to-earnings ratio of -285.50 and a beta of 0.92.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cambridge Investment Research Advisors Inc. bought a new stake in shares of Journey Medical in the second quarter valued at about $1,664,000. Acadian Asset Management LLC raised its stake in Journey Medical by 687.5% in the 1st quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock worth $817,000 after purchasing an additional 194,389 shares in the last quarter. PVG Asset Management Corp bought a new stake in Journey Medical in the 2nd quarter valued at about $894,000. Rosalind Advisors Inc. bought a new stake in Journey Medical in the 2nd quarter valued at about $644,000. Finally, Heron Bay Capital Management acquired a new position in shares of Journey Medical during the 1st quarter worth approximately $124,000. 7.25% of the stock is owned by institutional investors and hedge funds.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.